A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Last Updated February 22, 2025
Want to learn how to participate in this trial?
87704916LUC1001
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 11 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
CONDITIONS
- Advanced Solid Tumors
ELIGIBILITY
Inclusion Criteria:
* For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC
* Have at least 1 inject
DETAILS
LOCATIONS
| Country (3) | City or Province (7) | Status |
| United States | Philadelphia Fox Chase Cancer Center |
RECRUITING
|
| United States | Pittsburgh UPMC Cancer Centers |
RECRUITING
|
| United States | Houston MD Anderson Cancer Center |
RECRUITING
|
| France | Villejuif Gustave Roussy |
RECRUITING
|
| Spain | Barcelona Hosp Univ Vall D Hebron |
RECRUITING
|
| Spain | Madrid Hosp Univ Fund Jimenez Diaz |
RECRUITING
|
| Spain | Madrid Hosp Univ Hm Sanchinarro |
RECRUITING
|
39.95233, -75.16379
40.44062, -79.99589
29.76328, -95.36327
48.7939, 2.35992
41.38879, 2.15899
40.4165, -3.70256
40.4165, -3.70256
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.